Tarian Pharma Achievements in 2021

Tarian Pharma Achievements in 2021

Drug development achievements

  • CMC: Long term stability of TAR-0520 gel at 25°C and 40°C has been confirmed
  • Nonclinical: Completion of toxicology package allowing entrance in the first clinical study in cancer patients
  • Clinical Pharmacology: Demonstration of skin bioavailability and pharmacological performance over 24 hours with our lead candidate TAR-0520 gel
  • Clinical:Clinical sites to conduct the first study in patients selected

Intellectual Property

  • Patents filed in February 2021 and have entered PCT phase in February 2022


  • Tarian Pharma nominated in 2021 i-Lab contest
  • Tarian Pharma obtained Eurobiomed certification